Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic associations of eosinophilic granulomatosis with polyangiitis in the Japanese population: exploring similarities and differences with European populations.

RMD open·2026
Same author

A Delphi survey of patients and clinicians on a unified and stratified approach to managing GCA-PMR spectrum disease.

Rheumatology (Oxford, England)·2026
Same author

Retention Rates of Biological Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Reduced Kidney Function: Analysis From the IORRA Cohort.

International journal of rheumatic diseases·2026
Same author

Medical pre-training and fine-tuning improve large-language-model prediction of rheumatoid-arthritis disease activity.

Modern rheumatology·2026
Same author

Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study.

Rheumatology (Oxford, England)·2026
Same author

Differences in chest HRCT findings in relation to ANCA subtypes in ANCA-associated vasculitis.

Respiratory investigation·2026

Related Experiment Video

Updated: Jul 13, 2026

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

[CTLA4-Ig (abatacept)].

Masayoshi Harigai1

  • 1Tokyo Medical Dental University(Department of Pharmacovigilance.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 24, 2007
PubMed
Summary

Abatacept offers an effective treatment option for rheumatoid arthritis (RA) patients unresponsive to traditional therapies like methotrexate or tumor necrosis factor (TNF) antagonists. This biologic agent improves symptoms, quality of life, and slows joint damage, though safety monitoring for infections is crucial.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Context:

  • Rheumatoid arthritis (RA) poses a significant challenge, with many patients exhibiting resistance or intolerance to established treatments such as tumor necrosis factor (TNF) antagonists.
  • Abatacept represents a novel therapeutic approach targeting T-cell activation pathways.

Purpose:

  • To evaluate the efficacy and safety of abatacept in patients with rheumatoid arthritis (RA) who have not responded adequately to methotrexate or TNF antagonists.
  • To assess abatacept's impact on clinical outcomes, radiological progression, and quality of life in RA patients.

Summary:

  • Abatacept, a selective T-cell costimulation modulator, demonstrated significant clinical benefits in RA patients refractory to prior therapies.
  • Clinical trials confirmed abatacept's ability to improve signs and symptoms, enhance quality of life, and inhibit radiological progression of joint damage.

More Related Videos

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: Jul 13, 2026

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

  • The safety profile, particularly concerning infections and malignancies, requires careful monitoring in both clinical trials and real-world practice.

    • Impact:

    • Abatacept provides a valuable alternative for RA patients with inadequate response or intolerance to existing biologic therapies.
    • The findings support abatacept as an effective disease-modifying antirheumatic drug (DMARD) for a challenging patient subset.
    • Long-term safety surveillance is essential to fully understand the risk-benefit profile of abatacept in diverse patient populations.